Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
A diversified business allows the Swiss group to report a 14% sales rise for 2010, although pharma sales growth was just half that
You may also be interested in...
A Year After It Wins Ratiopharm, Teva Reaps Rewards in Europe
For innovator firms, Europe has been about surviving multiple price cuts and government austerity measures. For generics firms, it has become a land of opportunity, where 2011 growth will outpace the overall pharmaceutical market.
A Year After It Wins Ratiopharm, Teva Reaps Rewards in Europe
For innovator firms, Europe has been about surviving multiple price cuts and government austerity measures. For generics firms, it has become a land of opportunity, where 2011 growth will outpace the overall pharmaceutical market.
Novartis' Afinitor Goes To Panel Review With Trouble Areas For FDA
The Oncology Drugs Advisory Committee will review everolimus for certain advanced neuroendocrine tumors on April 12; the pivotal trial used progression-free survival and a crossover design, both areas that FDA has critiqued.